New HTA budget impact guidelines must not dissuade industry from investing in Ireland, says IPHA
This article was originally published in Scrip
Executive Summary
As the Irish government steels itself to request the European Union and the International Monetary Fund for a bailout of up to €90 billion to prop up its debt ridden banks, the Irish pharmaceutical industry association (IPHA) has cautioned against measures that might threaten international pharma investors. In particular, IPHA warns that new health technology appraisal guidelines published today on budget impact analysis (BIA) must not "result in any inadvertent delay in patient access to new health technologies" or dissuade companies from launching in Ireland.